"The approval makes Wegovy the first pill-based GLP-1 drug cleared specifically for weight management. It contains semaglutide, the same active ingredient used in the injection, the company said. Novo Nordisk said it expects to launch the pill in the US in early January. A 1.5 milligram starting dose will be available through pharmacies and select telehealth providers for $149 per month."
"It is also approved to help reduce the risk of serious cardiovascular events, such as heart attacks or strokes, in certain patients, the company said. In a late-stage clinical trial, over 300 patients taking the pill lost an average of 16.6% of their body weight over about 64 weeks when they stayed on treatment. Novo Nordisk said the result is comparable to the weight loss seen with the injectable version of Wegovy."
FDA approved a once-daily oral version of Wegovy that contains semaglutide, making it the first pill-based GLP-1 drug cleared specifically for weight management. Novo Nordisk plans a U.S. launch in early January with a 1.5 mg starting dose available through pharmacies and select telehealth providers for $149 per month. The pill is approved for adults with obesity or for those who are overweight with at least one weight-related health condition, and for reducing certain cardiovascular risks in eligible patients. In a late-stage trial, over 300 patients lost an average of 16.6% body weight over about 64 weeks on treatment. Common side effects include nausea, diarrhea, and vomiting. Novo Nordisk will provide more details on coverage and savings for higher doses and eligible patients ahead of launch.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]